<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05799222</url>
  </required_header>
  <id_info>
    <org_study_id>2022P001451</org_study_id>
    <nct_id>NCT05799222</nct_id>
  </id_info>
  <brief_title>Medically Intensive Nutrition Therapy Program for Obesity and Diabetes in a Low-income Population</brief_title>
  <acronym>MINT</acronym>
  <official_title>Feasibility Study of an Intensive Nutrition Therapy Program for Improvement of Obesity and Diabetes in a Low-income Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to better understand whether meal replacements can be an effective&#xD;
      tool for weight loss and treatment of elevated blood sugars in people with obesity/overweight&#xD;
      and diabetes/pre-diabetes who have a low income.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Medically Intensive Nutritional Therapy (MINT) program at Massachusetts General Hospital&#xD;
      (MGH) Weight Center is a low-calorie nutrition plan that may offer a solution for those who&#xD;
      have difficulty implementing a low-calorie dietary plan on their own. This study examines the&#xD;
      effects of MINT on weight loss and blood sugar control specifically in a low-income&#xD;
      population and explores potential reasons for discontinuing the program.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2023</start_date>
  <completion_date type="Anticipated">July 18, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 18, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Body weight reduction</measure>
    <time_frame>3 months</time_frame>
    <description>Reduction in body weight by greater than or equal to 5 percent</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemoglobin A1c reduction</measure>
    <time_frame>3 months</time_frame>
    <description>Reduction of Hemoglobin A1c by greater than or equal to 0.5 percent</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Program adherence</measure>
    <time_frame>3 months</time_frame>
    <description>Adherence with the program, and potential reasons for non-adherence as assessed with bi-weekly questionnaires</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Overweight</condition>
  <condition>PreDiabetes</condition>
  <condition>Diabetes Type 2</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Adults with overweight/obesity and pre-diabetes/diabetes and low income</arm_group_label>
    <description>Adults with overweight or obesity and pre-diabetes or type 2 diabetes who earn a low income.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Bariatrix Meal Replacement Products</intervention_name>
    <description>Meal replacement products offered through the Massachusetts General Hospital Weight Center.</description>
    <arm_group_label>Adults with overweight/obesity and pre-diabetes/diabetes and low income</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Participants may choose to take part in an optional collection of stored blood.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adults with overweight or obesity and pre-diabetes or diabetes and low income&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-65&#xD;
&#xD;
          -  Body mass index (BMI) greater than or equal to 27 kg/m^2&#xD;
&#xD;
          -  HgA1C greater than or equal to 5.7 percent or fasting glucose greater than or equal to&#xD;
             100mg/dL within the previous 6 months&#xD;
&#xD;
          -  Low-income as defined by having a family income at or below 400 percent of the federal&#xD;
             poverty level guidelines for 2022&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current use of antihyperglycemic agents (other than metformin) or approved anti-&#xD;
             obesity medications or plans to start such regimens over the 3 months post-study&#xD;
             enrollment&#xD;
&#xD;
          -  HbA1c greater than or equal to 10 percent&#xD;
&#xD;
          -  Plans to pursue bariatric surgery over the 6 months post-study enrollment&#xD;
&#xD;
          -  Weight loss of greater than 5 kg within the previous 3 months&#xD;
&#xD;
          -  Current active eating disorder, with the exception of binge eating disorder&#xD;
&#xD;
          -  Severe active psychiatric disease or significant cognitive impairment deemed by&#xD;
             investigator likely to impede adherence to piloted intervention&#xD;
&#xD;
          -  Active illicit substance abuse&#xD;
&#xD;
          -  Pregnant, breastfeeding, or considering pregnancy within the next 6 months&#xD;
&#xD;
          -  Current participation in another clinical research trial deemed by investigator to&#xD;
             conflict with current study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chika V Anekwe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mass General Brigham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chika V Anekwe, MD</last_name>
    <phone>617-726-4400</phone>
    <email>canekwe@mgh.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chika V Anekwe, MD</last_name>
      <phone>617-726-4400</phone>
      <email>canekwe@mgh.harvard.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 3, 2023</study_first_submitted>
  <study_first_submitted_qc>March 22, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2023</study_first_posted>
  <last_update_submitted>March 22, 2023</last_update_submitted>
  <last_update_submitted_qc>March 22, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Chika V. Anekwe, MD, MPH</investigator_full_name>
    <investigator_title>Instructor in Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no IPD plan.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

